Arcturus Therapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

• Arcturus Therapeutics Holdings Inc ARCT.OQ reported a quarterly adjusted loss of $1.03​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.11. The mean expectation of twelve analysts for the quarter was for a loss of 71 cents per share. Wall Street expected results to range from $-1.27 to -13 cents per share.

• Revenue fell 68.4% to $7.20 million from a year ago; analysts expected $17.67 million.

• Arcturus Therapeutics Holdings Inc's reported EPS for the quarter was a loss of $1.03​.

• The company reported a quarterly loss of $29.08 million.

• Arcturus Therapeutics Holdings Inc shares had risen by 36.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 6.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Arcturus Therapeutics Holdings Inc is $21.50, about 61.2% above its last closing price of $8.35

This summary was machine generated from LSEG data March 3 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)